Gefitinib (Iressa) is an anticancer drug against epidermal growth factor receptor (EGFR) on cancer cells, which combines with the receptor (EGFR) and blocks survival signaling through the receptor in target cancer cells, resulting in cancer cell death.
Gefitinib in Cancer Therapy
Although the target of gefitinib, EGFR, is widely expressed by epidermal cancer, e.g., cancers of lung, colorectal, breast, prostate, and skin, and other cancer types, e.g., cancers from bone, cartilage, fiber, muscle, fat, nerve, and blood vessels, etc., its action is limited. However, cancers with mutated EGFR tyrosine kinase (TK) gene or overactive EGFR are more sensitized to gefitinib, and it becomes very effective.
Mechanism of Action
Gefitinib selectively inhibits the EGFR tyrosine kinase domain by binding to the intracellular adenosine triphosphate (ATP)-binding site of the enzyme and blocks EGFR signaling. EGFR is a family of receptors which includes...
KeywordsEpidermal Growth Factor Receptor Epidermal Growth Factor Receptor Mutation Epidermal Growth Factor Receptor Gene Epidermal Growth Factor Receptor Signaling Epidermal Growth Factor Receptor Tyrosine Kinase
- Ramalingam SS, Blackhall F, Krzakowski M et al (2012) Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 30:3337–3344CrossRefPubMedGoogle Scholar
- Wang X, Goldstein D, Crowe PJ, Yang JL (2013) S3I-201, a novel STAT3 inhibitor, inhibits growth of human soft tissue sarcoma cell lines. World J Cancer Res 1:61–68Google Scholar
- (2012) Phosphatidylinositol-3,4,5-trisphosphate. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2866. doi: 10.1007/978-3-642-16483-5_4528Google Scholar
- (2012) Serine/Threonine Kinase. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3384. doi: 10.1007/978-3-642-16483-5_5258Google Scholar